AIM
URGN icon

Aigen Investment Management’s UroGen Pharma URGN Stock Holding History

Aigen Investment Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,712
Closed -$207K – 1080
2020
Q3 		$207K Sell
10,712
-38
-0.4% -$861 0.03% 640
2020
Q2 		$281K Buy
10,750
+2,244
+26% +$54.8K 0.04% 631
2020
Q1 		$152K Buy
8,506
+7,278
+593% +$197K 0.02% 786
2019
Q4 		$41K Buy
+1,228
New +$33.5K 0.01% 838

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Aigen Investment Management's URGN Position: Q4 2020 in Review

Aigen Investment Management sold out of UroGen Pharma (URGN) in Q4 2020, closing a stake of 10,712 shares — an estimated $207K sold.

Aigen Investment Management first reported a position in URGN in Q4 2019 and held it in 4 quarters. The position peaked at $281K in Q2 2020. 81 funds tracked by Wall St. Rank hold URGN as of Q4 2020.

  • Aigen Investment Management reported no remaining UroGen Pharma position as of Q4 2020 after selling out during the quarter.
  • Aigen Investment Management sold 10,712 UroGen Pharma shares in Q4 2020, an estimated $207K.
  • Aigen Investment Management first reported a position in UroGen Pharma in Q4 2019 and held it in 4 quarters.
  • Aigen Investment Management's UroGen Pharma position peaked at $281K in Q2 2020.
  • 81 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2020.

Based on Aigen Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.